A San Francisco based Venture Capital firm founded in 2016 is focused on early-stage healthcare companies. The firm currently has 29 companies in their portfolio, and has a network of family offices and high net worth individuals the firm shares deal flow with. The firm invests in all 4 life science sectors and the typical check size ranges from $100K – 500K in the form of equity or convertible notes. The firm generally seeks to make investments into emerging life science companies in Pre-Seed, Seed and Series A stages. The firm is US-focused in terms of geographic preference, but will occasionally look outside of the US.
The firm invests across all life science verticals and is open to all 4 sectors. The firm looks for novel technologies in biotech, medtech, digital health therapeutics, and diagnostics. In terms of biotech companies, the firm focuses on biotechnology platforms rather than single asset biotech companies. The firm is agnostic to both subsector and indication, and is open to both pre-clinical therapeutic companies as well as all three stages of medical devices.
The firm is open to all types of management teams, with a goal to democratize who gets funding in the life science space. The firm is looking for diversity in the management team to combine ideas and skill set. Bioverge prefers to co-invest rather than lead.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply